Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • Foghorn Therapeutics' Other Non-Current Assets rose 1709.6% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 1709.6%. This contributed to the annual value of $1.7 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Foghorn Therapeutics reported Other Non-Current Assets of $2.0 million as of Q3 2025, which was up 1709.6% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Other Non-Current Assets ranged from a high of $2.4 million in Q1 2022 and a low of $1.7 million during Q2 2023
  • In the last 5 years, Foghorn Therapeutics' Other Non-Current Assets had a median value of $1.7 million in 2021 and averaged $2.0 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first soared by 3866.13% in 2022, then tumbled by 2820.51% in 2023.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Other Non-Current Assets stood at $2.4 million in 2021, then fell by 0.88% to $2.4 million in 2022, then decreased by 28.21% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then rose by 17.1% to $2.0 million in 2025.
  • Its Other Non-Current Assets was $2.0 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.7 million in Q1 2025.